116 related articles for article (PubMed ID: 29902630)
1. The role of agonist-induced activation and inhibition for the regulation of purinergic receptor expression in human platelets.
Koessler J; Trulley VN; Bosch A; Weber K; Koessler A; Boeck M; Kobsar A
Thromb Res; 2018 Aug; 168():40-46. PubMed ID: 29902630
[TBL] [Abstract][Full Text] [Related]
2. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A
PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of TRAP-6-induced platelet dense granule release by blockade of P2Y
Mitrugno A; Rigg RA; Laschober NB; Ngo ATP; Pang J; Williams CD; Aslan JE; McCarty OJT
Platelets; 2018 Jun; 29(4):383-394. PubMed ID: 28523947
[TBL] [Abstract][Full Text] [Related]
5. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.
Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M
Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904
[TBL] [Abstract][Full Text] [Related]
6. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation.
Tseng YL; Chiang ML; Lane HY; Su KP; Lai YC
Thromb Res; 2013 Apr; 131(4):325-32. PubMed ID: 23490430
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
[TBL] [Abstract][Full Text] [Related]
9. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
10. Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects.
Oestreich JH; Steinhubl SR; Ferraris SP; Loftin CD; Akers WS
J Thromb Thrombolysis; 2014 Oct; 38(3):372-9. PubMed ID: 24510678
[TBL] [Abstract][Full Text] [Related]
11. Lipopolysaccharide (LPS) induced pulmonary neutrophil recruitment and platelet activation is mediated via the P2Y
Amison RT; Arnold S; O'Shaughnessy BG; Cleary SJ; Ofoedu J; Idzko M; Page CP; Pitchford SC
Pulm Pharmacol Ther; 2017 Aug; 45():62-68. PubMed ID: 28487256
[TBL] [Abstract][Full Text] [Related]
12. Off-target effect of the Epac agonist 8-pCPT-2'-O-Me-cAMP on P2Y12 receptors in blood platelets.
Herfindal L; Nygaard G; Kopperud R; Krakstad C; Døskeland SO; Selheim F
Biochem Biophys Res Commun; 2013 Aug; 437(4):603-8. PubMed ID: 23850619
[TBL] [Abstract][Full Text] [Related]
13. Specific inhibitory effects of the NO donor MAHMA/NONOate on human platelets.
Kobsar A; Simonis S; Klinker E; Koessler A; Kuhn S; Boeck M; Koessler J
Eur J Pharmacol; 2014 Jul; 735():169-76. PubMed ID: 24780647
[TBL] [Abstract][Full Text] [Related]
14. Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists.
Spath B; Hansen A; Bokemeyer C; Langer F
Platelets; 2012; 23(1):60-8. PubMed ID: 21736422
[TBL] [Abstract][Full Text] [Related]
15. Role of Purinergic Receptor Expression and Function for Reduced Responsiveness to Adenosine Diphosphate in Washed Human Platelets.
Koessler J; Hermann S; Weber K; Koessler A; Kuhn S; Boeck M; Kobsar A
PLoS One; 2016; 11(1):e0147370. PubMed ID: 26808867
[TBL] [Abstract][Full Text] [Related]
16. P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation.
Chan MV; Knowles RB; Lundberg MH; Tucker AT; Mohamed NA; Kirkby NS; Armstrong PC; Mitchell JA; Warner TD
Br J Clin Pharmacol; 2016 Apr; 81(4):621-33. PubMed ID: 26561399
[TBL] [Abstract][Full Text] [Related]
17. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
[TBL] [Abstract][Full Text] [Related]
18. Functional interaction between purinergic receptors: effect of ligands for A2A and P2Y12 receptors on P2Y1 receptor function.
Suzuki T; Obara Y; Moriya T; Nakata H; Nakahata N
FEBS Lett; 2011 Dec; 585(24):3978-84. PubMed ID: 22079667
[TBL] [Abstract][Full Text] [Related]
19. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
20. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
